SCHEMBL636423

SCHEMBL636423

COc1ccc2ccccc2c1Oc1ccccc1CC1CCNC1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
EED O75530 2/20 0.40
ATM Q13315 1/20 0.39
HCRTR1 O43613 3/20 0.38
HCRTR2 O43614 3/20 0.38
GNAI3 P08754 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
NISCH Q9Y2I1 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HTR2C P28335 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1155825 0.83 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3EEDGNAI3
SCHEMBL634531 0.82 EED (0.48) SLC6A2SLC6A4SLC6A3EEDATM
SCHEMBL3160580 0.78 EED (0.56) SLC6A2SLC6A4EEDGNAI3CYP2D6
SCHEMBL3897094 0.77 EED (0.52) SLC6A2SLC6A4SLC6A3EEDGNAI3
Oxalic Acid SCHEMBL5245645 0.76 MEN1 (0.47) SLC6A2SLC6A4MEN1KMT2AGNAI3
SCHEMBL1155985 0.75 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3EEDCYP2D6
SCHEMBL1705710 0.74 GNAI3 (0.57) SLC6A2SLC6A4SLC6A3GNAI3HTR2C
SCHEMBL6927391 0.74 SLC6A4 (0.48) SLC6A2SLC6A4SLC6A3ATMCYP2D6
SCHEMBL634784 0.74 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3EED
SCHEMBL1155843 0.73 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419405-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS Theravance, Inc. (US) 2012-02-22 EP disclosed
WO-2010120910-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS THERAVANCE, INC. (US) 2010-10-21 WO disclosed
US-20100267743-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS THERAVANCE BIOPHARMA R&D IP, LLC 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267743-A1 3-(PHENOXYPYRROLIDIN-3-YL-METHYL)HETEROARYL, 3-(PHENYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL, AND 3-(HETEROARYLPYRROLIDIN-3-YLMETHOXY)HETEROARYL COMPOUNDS HTR3C, SLC6A2, ADRB3 SLC6A2 2/4885SLC6A4 7/4885SLC6A3 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.